A Study to Examine the Safety and Efficacy of a New Drug in Patients With Symptoms of Overactive Bladder (OAB)

NCT03492281 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

1530

Enrollment

INDUSTRY

Sponsor class

Conditions

Overactive Bladder

Interventions

DRUG: vibegron
DRUG: Vibegron placebo
DRUG: Tolterodine Tartrate ER
DRUG: Tolterodine placebo

Sponsor

Urovant Sciences GmbH